DSG Partners With Biotech Company To Battle Progressive And Chronic Kidney Disease
Main Category: Urology / NephrologyAlso Included In: Clinical Trials / Drug Trials
Article Date: 03 Feb 2010 - 1:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
DSG's eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current phase 2 and phase 2a clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG's eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.
The result is clean clinical trial data, collected and analyzed efficiently. This accelerates the clinical trial process, helping to safely speed these treatments to those who need them.
The phase 2 study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in phase 2a, is a treatment for anemia in chronic kidney disease.
The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. eCaseLink™ EDC provides real-time, clean data, which facilitates quick data review, reporting and decision making for the company.
The eCaseLink™ system is a critical tool for the investigator site and monitoring personnel, in part because it greatly reduces the amount of time it takes to "lock" the clinical database. Database lock occurs once all data has been verified and cleaned through the data management process. Once "locked," the study's statistical analysis is performed and results are reported.
"Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG's unique eCaseLink™ EDC system to be employed in clinical trials," said Tony Varano, CEO of DSG.
Source
DSG Inc.
Visit our urology / nephrology section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/177957.php>
APA
http://www.medicalnewstoday.com/releases/177957.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



